Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Extensive stage small cell lung cancer.

H B Niell1

  • 1Van Vleet Cancer Center, University of Tennessee-Memphis, 3N Dunlap, Memphis, TN 38163, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary

Small cell lung cancer (SCLC) is aggressive, but chemotherapy offers improved survival for extensive disease. Standard treatment involves platinum and etoposide, with ongoing research into new agents and clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2005
Same author

Carboplatin/etoposide/paclitaxel in the treatment of patients with extensive small-cell lung cancer.

Clinical lung cancer·2004
Same author

Demyelination in the brain as a paraneoplastic disorder: candidates include some cases of leukemia and non-Hodgkin's lymphoma.

Annals of hematology·2003
Same author

Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide.

Lung cancer (Amsterdam, Netherlands)·2001
Same author

Efficacy of targeted chemoradiation and planned selective neck dissection to control bulky nodal disease in advanced head and neck cancer.

Archives of otolaryngology--head & neck surgery·1999
Same author

Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·1998

Area of Science:

  • Oncology
  • Pulmonology
  • Medical Oncology

Background:

  • Small cell lung cancer (SCLC) is a highly aggressive malignancy with a poor prognosis.
  • Most patients are diagnosed with extensive-stage disease, limiting curative treatment options.
  • Chemotherapy is the cornerstone of SCLC management, significantly impacting survival rates.

Purpose of the Study:

  • To summarize the current therapeutic landscape for extensive-stage small cell lung cancer.
  • To highlight the efficacy of standard chemotherapy regimens and the role of palliative radiation.
  • To emphasize the importance of clinical trial participation for advancing SCLC treatment.

Main Methods:

  • Review of current treatment standards for extensive-stage SCLC.
  • Analysis of the role of chemotherapy, radiation therapy, and surgery.
  • Discussion of first-line and second-line chemotherapy regimens.

Main Results:

  • Platinum and etoposide remain the standard first-line chemotherapy for SCLC.
  • Radiation therapy is primarily palliative in extensive disease.
  • Second-line chemotherapy shows moderate efficacy in responding patients.

Conclusions:

  • Modern chemotherapy significantly improves survival in extensive-stage SCLC.
  • Participation in clinical trials is crucial for developing novel therapies.
  • Further research is needed for new chemotherapy agents in extensive SCLC.

Related Experiment Videos